Marguerite Hutchinson, J.D.

Chief Business Officer

Marguerite Hutchinson, J.D., is Frontier's Chief Business Officer. Ms. Hutchinson was previously the Chief Operating Officer and General Counsel of Plexxikon, overseeing all finance and operational aspects of the company, including business development, legal affairs, intellectual property and project management. She started at Plexxikon in 2013, holding positions of increasing responsibility in business development and legal affairs. Her accomplishments include successfully pursuing the patent infringement case Plexxikon v. Novartis, out-licensing several Phase 2-ready small-molecule inhibitors to development and commercialization partners, and playing a pivotal role in the Phase 3 development plan for TURALIO®, which was approved in 2019 for the treatment of tenosynovial giant cell tumor (TGCT). Prior to Plexxikon, she was the lead attorney representing the UCSF Helen Diller Family Comprehensive Cancer Center in collaborations with industry and academic consortia. Ms. Hutchinson received a B.A. from Harvard University and a J.D. from the University of San Diego School of Law. She was recently named as one of the Top 25 Women Leaders in Biotech by the Healthcare Technology Report.